BioCryst stock: buy or sell?
June 26th, 2019
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
Should I buy BioCryst stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, BioCryst Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is BioCryst Pharmaceuticals stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we gathered 5 ratings published for BCRX stock in the last month. The general sentiment of these ratings is bullish for BCRX stock, with 3 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-5-24||Royal Bank of Canada||Outperform||Sector Perform|
|2019-5-22||Jefferies Financial Group||n/a||Buy|
|2019-4-22||Piper Jaffray Companies||n/a||Buy|
|2019-4-2||JMP Securities||Market Outperform||Market Outperform|
|2019-4-2||Barclays||Equal Weight||Equal Weight|
BioCryst stock analysis
Shares of BioCryst Pharmaceuticals closed today at $3.54 and eased a fateful -2.21%.
BioCryst Pharmaceuticals shares eased -2.21% to $3.54 today. For the last 41 days when BCRX stock price broke down the SMA200d line, it slid $-4.38 per share (-55.30%).
Late May BCRX plunged a hair-raising -120.78% in just one week. After boosting an amazing 8.13% in a week last week, BioCryst closed this week at $3.54 and slipped a terrible -4.07%.
BioCryst stock price history
BioCryst stock went public on March 4th, 1994 with a price of $6.251. Since then, BCRX stock declined a -43.40%, with a yearly average of -1.70%.
1: Adjusted price after possible price splits or reverse-splits.
BioCryst stock historical price chart
BCRX stock reached 52-week highs on January at $9.95, and all-time highs 2000-03-09 with a price of 37.25.
BioCryst stock price target is $10.70How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 5 price forecasts for BioCryst Pharmaceuticals stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-5-24||Royal Bank of Canada||Downgrades||$16.00||$4.50||-71.9%|
|2019-5-22||Jefferies Financial Group||Lowers Target||$13.00||$8.00||-38.5%|
|2019-4-22||Piper Jaffray Companies||Set Price Target||n/a||$15.00||-|
|2019-4-2||JMP Securities||Raises Target||$16.00||$18.00||12.5%|
Financials and fundamental analysis
Earnings date and Earnings per ShareBioCryst let down experts on March when it posted an Earnings per Share (EPS) of $-0.25 when the analysts' forecast was $-0.26.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, BioCryst Pharmaceuticals annual turnover plunged a frightening -18.00% to $20.65 M USD from $25.19 marked in 2017. Aligned with this, its income margin (compared to sales) plummed to -490.25%, that is $-101.25 million.
|2013||$17 M||-||$-30.11 M-173.7%||-|
|2014||$14 M||-21.48%||$-45.19 M-332.1%||50.08%|
|2015||$48 M||254.62%||$-43.02 M-89.1%||-4.80%|
|2016||$26 M||-45.39%||$-55.14 M-209.3%||28.19%|
|2017||$25 M||-4.43%||$-65.78 M-261.2%||19.29%|
|2018||$21 M||-18.00%||$-101.25 M-490.3%||53.92%|
Quarterly financial resultsBioCryst Pharmaceuticals posted $2.73 million in sales for 2018-Q4, a 87.69% improvement compared to previous quarter. Reported quarter income marked $-27.43 million with a profit margin of -1,005.20%. Profit margin skyrocketed a 1,030.35% compared to previous quarter when profit margin was -2,035.56%. When comparing turnover to same quarter last year, BioCryst sales marked a dreadful slide and collapsed a -29.85%.
|2017-Q1||$9 M||-||$-14.22 M-150.6%||-|
|2017-Q2||$3 M||-67.16%||$-16.89 M-544.8%||18.78%|
|2017-Q3||$9 M||182.58%||$-15.13 M-172.8%||-10.40%|
|2017-Q4||$4 M||-55.59%||$-19.54 M-502.4%||29.13%|
|2018-Q1||$4 M||2.21%||$-25.78 M-648.3%||31.90%|
|2018-Q2||$12 M||214.24%||$-18.45 M-147.6%||-28.44%|
|2018-Q3||$1 M||-88.36%||$-29.60 M-2035.6%||60.45%|
|2018-Q4||$3 M||87.69%||$-27.43 M-1005.2%||-7.31%|
BioCryst ownershipWhen you are planning to invest in a stock, it's always worth to overview its ownership structure.
BioCryst shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.04% of all shares.
Bearish positions for BCRX stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$390.5 M||$242.3 M||$2.4 B||$84.7 B||$197.5 B|
|Total shares||110.3 M||33.7 M||51.4 M||1,270.0 M||4,920.0 M|
|Float shares||60.2 M||31.6 M||43.1 M||1,270.0 M||2,440.0 M|
|- Institutional holdings (%)||93.6%||8.7%||85.4%||82.6%||11.0%|
|- Insider holdings (%)||1.0%||5.4%||14.9%||0.7%||0.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Wednesday, June 26th, 2019|
|Day range||$3.50 - $3.67|
|Average true range||$0.27|
|50d mov avg||$5.54|
|100d mov avg||$7.00|
|200d mov avg||$7.47|
BioCryst performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared BioCryst Pharmaceuticals against Cel-Sci, Emergent Biosolutions, Gilead Sciences, GlaxoSmithKline, NanoViricides, Repligen and Sarepta Therapeutics in the following table: